HistoIndex, CymaBay collaborate on phase 2 study of seladelpar for NASH

HistoIndex announced a collaboration with CymaBay to evaluate the efficacy of seladelpar for nonalcoholic steatohepatitis in a randomized control phase 2b study using HistoIndex’s Genesis 200 multiphoton digital pathology system, according to a press release.

“We are enthusiastic to work with CymaBay, and our passion synchronizes with their dedicated efforts to bring effective NASH therapeutics to patients,” Gideon Ho, PhD, CEO of HistoIndex, said in the release. “I am confident that our imaging technology will allow us to accurately quantify and track changes in fibrosis and relevant NASH characteristics such as steatosis, hepatocyte ballooning and lobular inflammation.”

The phase 2b study will comprise 175 patients with biopsy-confirmed NASH.

The Genesis 200 technology encompasses two-photon excitation and second harmonic generation with computerized image analysis to scan unstained tissue samples and quantify NASH characteristics.

“We are excited to be working with HistoIndex in our phase 2b study of seladelpar in patients with NASH,” Sujal Shah, CEO of CymaBay, added in the release. “We believe this collaboration offers us a unique opportunity to explore the Genesis 200 system to generate an innovative, data set evaluating the effects of seladelpar on NASH histology.” – by Talitha Bennett

Reference: www.histoindex.com; www.cymbabay.com

Disclosures: Ho is employed by HistoIndex and Shah is employed by CymaBay.